{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T07:09:09Z","timestamp":1793257749274,"version":"4.5.0"},"reference-count":295,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ejphar.2026.178913","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T15:54:00Z","timestamp":1777478040000},"page":"178913","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["From pathology to precision therapy: Contemporary and emerging strategies in Alzheimer's disease treatment"],"prefix":"10.1016","volume":"1025","author":[{"given":"Swetha","family":"Belavadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8961-3222","authenticated-orcid":false,"given":"Sunil Kumar","family":"Kadiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2026.178913_bib1","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1146\/annurev.immunol.14.1.483","article-title":"IMMUNOPHARMACOLOGY of rapamycin","volume":"14","author":"Abraham","year":"1996","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ejphar.2026.178913_bib2","series-title":"ALZFORUM","year":"2025"},{"key":"10.1016\/j.ejphar.2026.178913_bib3","series-title":"ALZFORUM","year":"2021"},{"key":"10.1016\/j.ejphar.2026.178913_bib4","series-title":"Alzheimer's Disease International","year":"2020"},{"key":"10.1016\/j.ejphar.2026.178913_bib5","unstructured":"Aduhelm [WWW Document], n.d. ALZFORUM. URL https:\/\/www.alzforum.org\/therapeutics\/aduhelm (accessed 8.28.25)."},{"key":"10.1016\/j.ejphar.2026.178913_bib6","author":"Aggidis"},{"key":"10.1016\/j.ejphar.2026.178913_bib7","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13195-022-00959-z","article-title":"A novel D-amino acid peptide with therapeutic potential (ISAD1) inhibits aggregation of neurotoxic disease-relevant mutant tau and prevents Tau toxicity in vitro","volume":"14","author":"Aillaud","year":"2022","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.ejphar.2026.178913_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/ph15101283","article-title":"Strategies for improving peptide stability and delivery","volume":"15","author":"Al Musaimi","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.ejphar.2026.178913_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0068159","article-title":"Anti-aggregating effect of the naturally occurring dipeptide carnosine on A\u03b21-42 fibril formation","volume":"8","author":"Aloisi","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2026.178913_bib10","first-page":"72","article-title":"Unraveling Alzheimer's: the promise of aducanumab, lecanemab, and donanemab. Egypt","volume":"60","author":"Ameen","year":"2024","journal-title":"J. Neurol. Psychiatr. Neurosurg."},{"key":"10.1016\/j.ejphar.2026.178913_bib11","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12974-019-1494-4","article-title":"Antibiotics, gut microbiota, and Alzheimer's disease","volume":"16","author":"Angelucci","year":"2019","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.ejphar.2026.178913_bib12","doi-asserted-by":"crossref","first-page":"8236","DOI":"10.1002\/anie.201405109","article-title":"Rational design and identification of a non\u2010peptidic aggregation inhibitor of Amyloid\u2010\u03b2 based on a pharmacophore motif obtained from cyclo [\u2010Lys\u2010Leu\u2010Val\u2010Phe\u2010Phe\u2010]","volume":"53","author":"Arai","year":"2014","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejphar.2026.178913_bib13","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1002\/cbic.201402430","article-title":"A cyclic KLVFF\u2010Derived peptide aggregation inhibitor induces the formation of less\u2010toxic off\u2010pathway Amyloid\u2010\u03b2 oligomers","volume":"15","author":"Arai","year":"2014","journal-title":"Chembiochem"},{"key":"10.1016\/j.ejphar.2026.178913_bib14","doi-asserted-by":"crossref","first-page":"7384","DOI":"10.1002\/alz.14063","article-title":"Pathways to personalized medicine-embracing heterogeneity for progress in clinical therapeutics research in Alzheimer's disease","volume":"20","author":"Arnold","year":"2024","journal-title":"Alzheimer's Dement."},{"key":"10.1016\/j.ejphar.2026.178913_bib15","series-title":"Update on Phase III Clinical Trials of Lanabecestat for Alzheimer's Disease","year":"2018"},{"key":"10.1016\/j.ejphar.2026.178913_bib16","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0896-6273(00)00035-0","article-title":"The TrkB-Shc site signals neuronal survival and local axon growth via MEK and PI3-Kinase","volume":"27","author":"Atwal","year":"2000","journal-title":"Neuron"},{"key":"10.1016\/j.ejphar.2026.178913_bib17","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1021\/bi701415b","article-title":"Designing peptide inhibitors for oligomerization and toxicity of alzheimer's \u03b2-Amyloid peptide","volume":"47","author":"Austen","year":"2008","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejphar.2026.178913_bib18","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb2639","article-title":"Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer's disease","volume":"13","author":"Ayalon","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejphar.2026.178913_bib19","series-title":"ALZFORUM","year":"2021"},{"key":"10.1016\/j.ejphar.2026.178913_bib20","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2174\/1389450043345290","article-title":"\u03b2-Sheet breakers for alzheimers disease therapy","volume":"5","author":"B","year":"2004","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.ejphar.2026.178913_bib21","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.3390\/ijms21031094","article-title":"Aggregation mechanism of alzheimer's amyloid \u03b2-Peptide mediated by \u03b1-Strand\/\u03b1-Sheet structure","volume":"21","author":"Balupuri","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2026.178913_bib22","doi-asserted-by":"crossref","first-page":"10019","DOI":"10.1021\/acsomega.8b01522","article-title":"C-Terminal fragment, A\u03b2 39\u201342 -Based tetrapeptides mitigates Amyloid-\u03b2 aggregation-induced toxicity","volume":"3","author":"Bansal","year":"2018","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejphar.2026.178913_bib23","unstructured":"Bapineuzumab [WWW Document], n.d. . ALZFORUM. URL https:\/\/www.alzforum.org\/therapeutics\/bapineuzumab (accessed 8.28.25)."},{"key":"10.1016\/j.ejphar.2026.178913_bib24","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1001\/jama.1977.03280220061024","article-title":"Reversal of central anticholinergic syndrome by galanthamine","volume":"238","author":"Baraka","year":"1977","journal-title":"JAMA, J. Am. Med. Assoc."},{"key":"10.1016\/j.ejphar.2026.178913_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2019.00204","article-title":"Role of tau as a microtubule-associated protein: structural and functional aspects","volume":"11","author":"Barbier","year":"2019","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.ejphar.2026.178913_bib26","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000205138","article-title":"Dual amyloid beta\/tau vaccine PRX123 surrogate results in robust clearance of amyloid plaques in brains of aggressive APP\/PS1 mouse model (P7-9.015)","volume":"102","author":"Barbour","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2026.178913_bib27","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jalz.2016.07.005","article-title":"The DIAN\u2010TU next generation Alzheimer's prevention trial: adaptive design and disease progression model","volume":"13","author":"Bateman","year":"2017","journal-title":"Alzheimer's Dementia"},{"key":"10.1016\/j.ejphar.2026.178913_bib28","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1056\/NEJMoa2304430","article-title":"Two phase 3 trials of gantenerumab in early alzheimer's disease","volume":"389","author":"Bateman","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2026.178913_bib29","doi-asserted-by":"crossref","first-page":"8823","DOI":"10.3390\/molecules27248823","article-title":"BACE1 inhibitors for alzheimer's disease: the past, present and any future?","volume":"27","author":"Bazzari","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.ejphar.2026.178913_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2022.105748","article-title":"Association between lower body temperature and increased tau pathology in cognitively normal older adults","volume":"171","author":"Blessing","year":"2022","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ejphar.2026.178913_bib31","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1001\/jamaneurol.2013.5847","article-title":"Amyloid-\u03b2 and tau : the trigger and bullet in alzheimer disease pathogenesis","volume":"71","author":"Bloom","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ejphar.2026.178913_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.jalz.2015.06.1655","article-title":"P3\u2010282: single oral doses of the novel bace inhibitor bi 1181181 significantly reduce concentrations of cerebrospinal fluid amyloid\u2010beta peptides in healthy subjects","volume":"11","author":"Borta","year":"2015","journal-title":"Alzheimer's Dementia"},{"key":"10.1016\/j.ejphar.2026.178913_bib33","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.actbio.2008.09.018","article-title":"Self-assembling materials for therapeutic delivery","volume":"5","author":"Branco","year":"2009","journal-title":"Acta Biomater."},{"key":"10.1016\/j.ejphar.2026.178913_bib34","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s40261-017-0549-5","article-title":"Pharmacokinetics of cromolyn and ibuprofen in healthy elderly volunteers","volume":"37","author":"Brazier","year":"2017","journal-title":"Clin. Drug Invest."},{"key":"10.1016\/j.ejphar.2026.178913_bib35","series-title":"Umibecestat Alzheimer Disease Prevention Trials Discontinued","author":"Brian","year":"2019"},{"key":"10.1016\/j.ejphar.2026.178913_bib36","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.3390\/biomedicines10092261","article-title":"The role of glymphatic system in alzheimer's and parkinson's disease pathogenesis","volume":"10","author":"Buccellato","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejphar.2026.178913_bib37","series-title":"LBA 3. International Parkinson's and Movement Disorder Society","article-title":"A randomised, placebo-controlled, first-in-human study with a central tau epitope antibody \u2013 UCB0107","author":"Buchanan","year":"2019"},{"key":"10.1016\/j.ejphar.2026.178913_bib38","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3233\/JAD-2010-1375","article-title":"Oxidatively modified Glyceraldehyde-3-Phosphate dehydrogenase (GAPDH) and alzheimer's disease: many pathways to neurodegeneration","volume":"20","author":"Butterfield","year":"2010","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.ejphar.2026.178913_bib39","first-page":"303","article-title":"Donepezil in Alzheimer's disease: from conventional trials to pharmacogenetics","volume":"3","author":"Cacabelos","year":"2007","journal-title":"Neuropsychiatric Dis. Treat."},{"key":"10.1016\/j.ejphar.2026.178913_bib40","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/epi.17186","article-title":"Seizure activity triggers tau hyperphosphorylation and amyloidogenic pathways","volume":"63","author":"Canet","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejphar.2026.178913_bib41","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s13287-024-03737-w","article-title":"Promoting Alzheimer's disease research and therapy with stem cell technology","volume":"15","author":"Cao","year":"2024","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.ejphar.2026.178913_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctim.2019.102294","article-title":"Oxidative stress in alzheimer's disease: a review on emergent natural polyphenolic therapeutics","volume":"49","author":"Cassidy","year":"2020","journal-title":"Compl. Ther. Med."},{"key":"10.1016\/j.ejphar.2026.178913_bib43","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jns.2012.07.023","article-title":"Epidemiology of dementia in Asia: insights on prevalence, trends and novel risk factors","volume":"321","author":"Catindig","year":"2012","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.ejphar.2026.178913_bib44","doi-asserted-by":"crossref","first-page":"34874","DOI":"10.1074\/jbc.M212694200","article-title":"Stereoselective interactions of peptide inhibitors with the \u03b2-Amyloid peptide","volume":"278","author":"Chalifour","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2026.178913_bib45","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1177\/1947601910383564","article-title":"Inhibition of notch signaling blocks growth of glioblastoma cell lines and tumor neurospheres","volume":"1","author":"Chen","year":"2010","journal-title":"Genes Cancer"},{"key":"10.1016\/j.ejphar.2026.178913_bib46","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1021\/acschemneuro.1c00181","article-title":"Optimized TrkB agonist ameliorates alzheimer's disease pathologies and improves cognitive functions via inhibiting delta-secretase","volume":"12","author":"Chen","year":"2021","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejphar.2026.178913_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2025.100366","article-title":"The role for artificial intelligence in identifying combination therapies for Alzheimer's disease","volume":"12","author":"Cheng","year":"2025","journal-title":"J. Prev. Alzheimers Dis."},{"key":"10.1016\/j.ejphar.2026.178913_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12017-009-8104-z","article-title":"An overview of APP processing enzymes and products","volume":"12","author":"Chow","year":"2010","journal-title":"Neuromolecular Med."},{"key":"10.1016\/j.ejphar.2026.178913_bib49","doi-asserted-by":"crossref","first-page":"918","DOI":"10.2174\/1567205011666141107150331","article-title":"Structure and mechanism of action of Tau aggregation inhibitors","volume":"11","author":"Cisek","year":"2014","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.ejphar.2026.178913_bib50","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.conb.2019.11.022","article-title":"Prion-like properties of Tau assemblies","volume":"61","author":"Clavaguera","year":"2020","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.ejphar.2026.178913_bib51","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.immuni.2010.10.002","article-title":"Vaccine adjuvants: putting innate immunity to work","volume":"33","author":"Coffman","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.ejphar.2026.178913_bib52","article-title":"Celecoxib","author":"Cohen","year":"2024","journal-title":"StatPearls"},{"key":"10.1016\/j.ejphar.2026.178913_bib53","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1750-1326-2-22","article-title":"The Alzheimer's disease beta-secretase enzyme, BACE1","volume":"2","author":"Cole","year":"2007","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.ejphar.2026.178913_bib54","doi-asserted-by":"crossref","first-page":"6743","DOI":"10.1523\/JNEUROSCI.1381-10.2010","article-title":"Acute \u03b3-Secretase inhibition of nonhuman primate CNS shifts amyloid precursor protein (APP) metabolism from Amyloid-\u03b2 production to alternative APP fragments without Amyloid-\u03b2 rebound","volume":"30","author":"Cook","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejphar.2026.178913_bib55","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1001\/archneurol.2012.2194","article-title":"Safety and tolerability of the \u03b3-Secretase inhibitor avagacestat in a phase 2 study of mild to moderate alzheimer disease","volume":"69","author":"Coric","year":"2012","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.ejphar.2026.178913_bib56","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/cbdd.12055","article-title":"The future of peptide\u2010based drugs","volume":"81","author":"Craik","year":"2013","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejphar.2026.178913_bib57","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1080\/09540260802094548","article-title":"Controversies in Alzheimer's disease drug development","volume":"20","author":"Cummings","year":"2008","journal-title":"Int. Rev. Psychiatr."},{"key":"10.1016\/j.ejphar.2026.178913_bib58","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3233\/JAD-180766","article-title":"Treatment combinations for alzheimer's disease: current and future pharmacotherapy options","volume":"67","author":"Cummings","year":"2019","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.ejphar.2026.178913_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2025.100328","article-title":"Alzheimer combination therapies: overview and scenarios","volume":"12","author":"Cummings","year":"2025","journal-title":"J. Prev. Alzheimers Dis."},{"key":"10.1016\/j.ejphar.2026.178913_bib60","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1038\/s41467-025-56690-4","article-title":"Drug repurposing for Alzheimer's disease and other neurodegenerative disorders","volume":"16","author":"Cummings","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejphar.2026.178913_bib61","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41467-026-68374-8","article-title":"The glymphatic system clears amyloid beta and tau from brain to plasma in humans","volume":"17","author":"Dagum","year":"2026","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejphar.2026.178913_bib62","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0167432","article-title":"Selection and characterization of tau binding \u1d05-Enantiomeric peptides with potential for therapy of alzheimer disease","volume":"11","author":"Dammers","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2026.178913_bib63","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.bpj.2014.12.013","article-title":"Alzheimer's protective A2T mutation changes the conformational landscape of the A\u03b21\u201342 monomer differently than does the A2V mutation","volume":"108","author":"Das","year":"2015","journal-title":"Biophys. J."},{"key":"10.1016\/j.ejphar.2026.178913_bib64","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.nbd.2004.08.007","article-title":"In vitro model of neurotoxicity of A? 1?42 and neuroprotection by a pentapeptide: irreversible events during the first hour","volume":"17","author":"Datki","year":"2004","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ejphar.2026.178913_bib65","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0140-6736(76)91936-X","article-title":"Selective loss of central cholinergic neurons in ALZHEIMER\u2019S disease","volume":"308","author":"Davies","year":"1976","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2026.178913_bib66","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/neu.480251103","article-title":"The role of neurotrophins in the developing nervous system","volume":"25","author":"Davies","year":"1994","journal-title":"J. Neurobiol."},{"key":"10.1016\/j.ejphar.2026.178913_bib67","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/jnc.12675","article-title":"Insights into the physiological function of the \u03b2\u2010amyloid precursor protein: beyond Alzheimer's disease","volume":"129","author":"Dawkins","year":"2014","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejphar.2026.178913_bib68","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrneurol.2009.218","article-title":"The secretases: enzymes with therapeutic potential in alzheimer disease","volume":"6","author":"De Strooper","year":"2010","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.ejphar.2026.178913_bib69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/OAJCT.S221914","article-title":"MCLENA-1: a phase II clinical trial for the assessment of safety, tolerability, and efficacy of lenalidomide in patients with mild cognitive impairment due to Alzheimer's disease","volume":"12","author":"Decourt","year":"2020","journal-title":"Open Access J. Clin. Trials"},{"key":"10.1016\/j.ejphar.2026.178913_bib70","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.bbcan.2016.05.003","article-title":"Nerve growth factor & TrkA as novel therapeutic targets in cancer","volume":"1866","author":"Demir","year":"2016","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"key":"10.1016\/j.ejphar.2026.178913_bib71","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0122451","article-title":"Peptides of Presenilin-1 bind the amyloid precursor protein ectodomain and offer a novel and specific therapeutic approach to reduce \u00df-Amyloid in alzheimer's disease","volume":"10","author":"Dewji","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2026.178913_bib72","doi-asserted-by":"crossref","DOI":"10.1038\/srep20949","article-title":"Tackling amyloidogenesis in Alzheimer's disease with A2V variants of Amyloid-\u03b2","volume":"6","author":"Di Fede","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2026.178913_bib73","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70709","article-title":"Glymphatic and meningeal lymphatic dysfunction in Alzheimer's disease: mechanisms and therapeutic perspectives","volume":"21","author":"Ding","year":"2025","journal-title":"Alzheimer's Dement."},{"key":"10.1016\/j.ejphar.2026.178913_bib74","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.nbd.2016.01.006","article-title":"The new \u03b2 amyloid-derived peptide A\u03b21\u20136A2V-TAT(D) prevents A\u03b2 oligomer formation and protects transgenic C. elegans from A\u03b2 toxicity","volume":"88","author":"Diomede","year":"2016","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ejphar.2026.178913_bib75","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1021\/acschemneuro.7b00188","article-title":"Why is research on Amyloid-\u03b2 failing to give new drugs for alzheimer's disease?","volume":"8","author":"Doig","year":"2017","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejphar.2026.178913_bib76","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.647742","article-title":"Insight into the role of the STriatal-Enriched protein tyrosine phosphatase (STEP) in A2A receptor-mediated effects in the central nervous system","volume":"12","author":"Domenici","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.178913_bib77","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1210951","article-title":"A phase 3 trial of semagacestat for treatment of alzheimer's disease","volume":"369","author":"Doody","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2026.178913_bib78","unstructured":"Drug repurposing: Approaches and Methods, n.d. ELSEVIER."},{"key":"10.1016\/j.ejphar.2026.178913_bib79","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1033479","article-title":"The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer's disease","volume":"13","author":"Du","year":"2022","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.ejphar.2026.178913_bib80","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2022.838173","article-title":"Exploring the pharmacological potential of metformin for neurodegenerative diseases","volume":"14","author":"Du","year":"2022","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.ejphar.2026.178913_bib81","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s13311-022-01185-z","article-title":"Heterogeneity in alzheimer's disease diagnosis and progression rates: implications for therapeutic trials","volume":"19","author":"Duara","year":"2022","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.ejphar.2026.178913_bib82","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1016\/j.febslet.2008.05.002","article-title":"p3 peptide, a truncated form of A\u03b2 devoid of synaptotoxic effect, does not assemble into soluble oligomers","volume":"582","author":"Dulin","year":"2008","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ejphar.2026.178913_bib83","article-title":"Aduhelm: biogen abandons Alzheimer's drug after controversial approval left it unfunded by medicare","volume":"q281","author":"Dyer","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.ejphar.2026.178913_bib84","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jamaneurol.2023.3861","article-title":"Exploratory tau biomarker results from a multiple ascending-dose study of BIIB080 in alzheimer disease","volume":"80","author":"Edwards","year":"2023","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ejphar.2026.178913_bib85","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1706441","article-title":"Randomized trial of verubecestat for mild-to-moderate alzheimer's disease","volume":"378","author":"Egan","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2026.178913_bib86","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1212\/WNL.0000000000001017","article-title":"Increased CSF APPs-\u03b1 levels in patients with alzheimer disease treated with acitretin","volume":"83","author":"Endres","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2026.178913_bib87","series-title":"ALZFORUM","year":"2014"},{"key":"10.1016\/j.ejphar.2026.178913_bib88","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2458\/lymph.9753","article-title":"Manual lymph drainage for alzheimer's dementia: a clinical trial whose time has come?","volume":"58","author":"Erickson","year":"2025","journal-title":"Lymphology"},{"key":"10.1016\/j.ejphar.2026.178913_bib89","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1021\/ja0600678","article-title":"Stoichiometric inhibition of amyloid \u03b2-Protein aggregation with peptides containing alternating \u03b1,\u03b1-Disubstituted amino acids","volume":"128","author":"Etienne","year":"2006","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejphar.2026.178913_bib90","series-title":"Exelon: Slowing Alzheimer's Disease","year":"2019"},{"key":"10.1016\/j.ejphar.2026.178913_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e17488","article-title":"Advances in drug delivery systems, challenges and future directions","volume":"9","author":"Ezike","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.ejphar.2026.178913_bib92","doi-asserted-by":"crossref","first-page":"819","DOI":"10.3390\/vaccines10050819","article-title":"An overview of vaccine adjuvants: current evidence and future perspectives","volume":"10","author":"Facciol\u00e0","year":"2022","journal-title":"Vaccines (Basel)."},{"key":"10.1016\/j.ejphar.2026.178913_bib93","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41541-024-00942-9","article-title":"A multi-targeting immunotherapy ameliorates multiple facets of Alzheimer's disease in 3xTg mice","volume":"9","author":"Feng","year":"2024","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.ejphar.2026.178913_bib94","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.bbrc.2011.02.067","article-title":"The effect of tachykinin neuropeptides on amyloid \u03b2 aggregation","volume":"407","author":"Flashner","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejphar.2026.178913_bib95","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000208061","article-title":"Assessment of efficacy and safety of zagotenemab","volume":"102","author":"Fleisher","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2026.178913_bib96","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.3390\/molecules28052413","article-title":"Therapeutic effects of coumarins with different substitution patterns","volume":"28","author":"Flores-Morales","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.ejphar.2026.178913_bib97","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1093\/brain\/awad024","article-title":"Tilavonemab in early Alzheimer's disease: results from a phase 2, randomized, double-blind study","volume":"146","author":"Florian","year":"2023","journal-title":"Brain"},{"key":"10.1016\/j.ejphar.2026.178913_bib98","doi-asserted-by":"crossref","first-page":"18150","DOI":"10.1074\/jbc.RA119.008837","article-title":"Pharmacologically diverse antidepressants facilitate TRKB receptor activation by disrupting its interaction with the endocytic adaptor complex AP-2","volume":"294","author":"Fred","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2026.178913_bib99","doi-asserted-by":"crossref","first-page":"11157","DOI":"10.1523\/JNEUROSCI.2884-10.2010","article-title":"A noncompetitive BACE1 inhibitor TAK-070 ameliorates A\u03b2 pathology and behavioral deficits in a mouse model of alzheimer's disease","volume":"30","author":"Fukumoto","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejphar.2026.178913_bib100","first-page":"27","author":"Ghosh","year":"2016"},{"key":"10.1016\/j.ejphar.2026.178913_bib101","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1124\/pr.110.003053","article-title":"Therapeutic implications for striatal-enriched protein tyrosine phosphatase (STEP) in neuropsychiatric disorders","volume":"64","author":"Goebel-Goody","year":"2012","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejphar.2026.178913_bib102","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1016\/j.bbamem.2013.06.005","article-title":"\u03b3-Secretase inhibitors and modulators","volume":"1828","author":"Golde","year":"2013","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"10.1016\/j.ejphar.2026.178913_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.jphotobiol.2024.113086","article-title":"Near-infrared light therapy normalizes amyloid load, neuronal lipid membrane order, rafts and cholesterol level in Alzheimer's disease","volume":"262","author":"Golovynska","year":"2025","journal-title":"J. Photochem. Photobiol., B"},{"key":"10.1016\/j.ejphar.2026.178913_bib104","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s43856-025-00904-9","article-title":"Rapamycin treatment for Alzheimer's disease and related dementias: a pilot phase 1 clinical trial","volume":"5","author":"Gonzales","year":"2025","journal-title":"Commun. Med."},{"key":"10.1016\/j.ejphar.2026.178913_bib105","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1021\/acscombsci.6b00116","article-title":"Rationally designed peptides and peptidomimetics as inhibitors of Amyloid-\u03b2 (A\u03b2) aggregation: potential therapeutics of alzheimer's disease","volume":"19","author":"Goyal","year":"2017","journal-title":"ACS Comb. Sci."},{"key":"10.1016\/j.ejphar.2026.178913_bib106","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-72989-2","article-title":"Hyaluronan-carnosine conjugates inhibit A\u03b2 aggregation and toxicity","volume":"10","author":"Greco","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2026.178913_bib107","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1001\/jama.2009.1866","article-title":"Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild alzheimer disease<subtitle>a randomized controlled trial<\/subtitle>","volume":"302","author":"Green","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.ejphar.2026.178913_bib108","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2261509","article-title":"Delivery of the BrainshuttleTM amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans","volume":"15","author":"Grimm","year":"2023","journal-title":"mAbs"},{"key":"10.1016\/j.ejphar.2026.178913_bib109","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jconrel.2023.12.030","article-title":"Erythrocyte membrane-coated nanocarriers modified by TGN for Alzheimer's disease","volume":"366","author":"Gu","year":"2024","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.ejphar.2026.178913_bib110","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.celrep.2017.06.023","article-title":"Silent allosteric modulation of mGluR5 maintains glutamate signaling while rescuing alzheimer's mouse phenotypes","volume":"20","author":"Haas","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejphar.2026.178913_bib111","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.biopsych.2020.02.001","article-title":"The \u03b2-Secretase BACE1 in alzheimer's disease","volume":"89","author":"Hampel","year":"2021","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.ejphar.2026.178913_bib112","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.bbadis.2006.01.012","article-title":"GAPDH as a sensor of NO stress","volume":"1762","author":"Hara","year":"2006","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"10.1016\/j.ejphar.2026.178913_bib113","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nrn2911","article-title":"Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders","volume":"11","author":"Hardingham","year":"2010","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.ejphar.2026.178913_bib114","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1096\/fasebj.4.6.1969374","article-title":"Diversity in Mammalian tachykinin peptidergic neurons: multiple peptides, receptors, and regulatory mechanisms 1","volume":"4","author":"Helke","year":"1990","journal-title":"FASEB J."},{"key":"10.1016\/j.ejphar.2026.178913_bib115","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4103\/1673-5374.313016","article-title":"Presenilin mutations and their impact on neuronal differentiation in Alzheimer's disease","volume":"17","author":"Hernandez-Sapiens","year":"2022","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.ejphar.2026.178913_bib116","doi-asserted-by":"crossref","first-page":"101","DOI":"10.31887\/DCNS.2003.5.1\/hhippius","article-title":"The discovery of Alzheimer's disease","volume":"5","author":"Hippius","year":"2003","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.ejphar.2026.178913_bib117","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.pnpbp.2017.01.003","article-title":"The pharmacology of tacrine at N -methyl- d -aspartate receptors","volume":"75","author":"Horak","year":"2017","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.ejphar.2026.178913_bib118","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.neuro.24.1.677","article-title":"Neurotrophins: roles in neuronal development and function","volume":"24","author":"Huang","year":"2001","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.ejphar.2026.178913_bib119","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s12276-022-00754-8","article-title":"\u03b3-Secretase in Alzheimer's disease","volume":"54","author":"Hur","year":"2022","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.ejphar.2026.178913_bib120","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.2353\/ajpath.2010.100346","article-title":"A\u03b2 accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an alzheimer mouse model","volume":"177","author":"Hurtado","year":"2010","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ejphar.2026.178913_bib121","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/a89c089f-ae9d-4453-a314-37efd5efb126","article-title":"The novel gamma secretase inhibitor RO4929097 reduces the tumor initiating potential of melanoma","volume":"6","author":"Huynh","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2026.178913_bib122","article-title":"Are NSAIDs useful to treat Alzheimer's disease or mild cognitive impairment?","year":"2010","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.ejphar.2026.178913_bib123","doi-asserted-by":"crossref","first-page":"4615","DOI":"10.1021\/acs.joc.8b03001","article-title":"Sustainability challenges in peptide synthesis and purification: from R& D to production","volume":"84","author":"Isidro-Llobet","year":"2019","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.ejphar.2026.178913_bib124","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/prot.26057","article-title":"\u03b2\u2010sheet breakers with consecutive phenylalanines: insights into mechanism of dissolution of \u03b2\u2010amyloid fibrils","volume":"89","author":"Jarmu\u0142a","year":"2021","journal-title":"Proteins: Struct., Funct., Bioinf."},{"key":"10.1016\/j.ejphar.2026.178913_bib125","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1021\/bi00069a001","article-title":"The carboxy terminus of the .beta. Amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease","volume":"32","author":"Jarrett","year":"1993","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejphar.2026.178913_bib126","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006378.pub2","article-title":"Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease","author":"Jaturapatporn","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejphar.2026.178913_bib127","doi-asserted-by":"crossref","first-page":"41245","DOI":"10.1074\/jbc.M112.409110","article-title":"Discovery of AZD3839, a potent and selective BACE1 inhibitor clinical candidate for the treatment of alzheimer disease","volume":"287","author":"Jeppsson","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2026.178913_bib128","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3390\/cancers12010147","article-title":"Roles of TrkC signaling in the regulation of tumorigenicity and metastasis of","volume":"12","author":"Jin","year":"2020","journal-title":"Cancer. Cancers (Basel)"},{"key":"10.1016\/j.ejphar.2026.178913_bib130","series-title":"Alzheimer's Disease: Drug Discovery","first-page":"51","article-title":"Amyloid \u00df-Targeted inhibitory peptides for alzheimer's disease: Current state and future perspectives","author":"Jokar","year":"2020"},{"key":"10.1016\/j.ejphar.2026.178913_bib131","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature11283","article-title":"A mutation in APP protects against Alzheimer's disease and age-related cognitive decline","volume":"488","author":"Jonsson","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2026.178913_bib132","series-title":"Immunogenicity and Target Engagement of ACI-24 Formulations in Patients with Mild Alzheimer's Disease","article-title":"A phase II double-blind, randomized, placebo-controlled, adaptive design study to assess the safety, tolerability","author":"Julien","year":"2022"},{"key":"10.1016\/j.ejphar.2026.178913_bib133","doi-asserted-by":"crossref","first-page":"27137","DOI":"10.1039\/D0RA04788K","article-title":"Effect of C-terminus amidation of A\u03b2 39\u201342 fragment derived peptides as potential inhibitors of A\u03b2 aggregation","volume":"10","author":"Kapadia","year":"2020","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejphar.2026.178913_bib134","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1074-5521(03)00022-X","article-title":"Conformational restriction via cyclization in \u03b2-Amyloid peptide A\u03b2(1-28) leads to an inhibitor of A\u03b2(1-28) amyloidogenesis and cytotoxicity","volume":"10","author":"Kapurniotu","year":"2003","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ejphar.2026.178913_bib135","doi-asserted-by":"crossref","first-page":"18340","DOI":"10.1021\/jacs.3c03980","article-title":"A hairpin motif in the Amyloid-\u03b2 peptide is important for formation of disease-related oligomers","volume":"145","author":"Khaled","year":"2023","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejphar.2026.178913_bib136","first-page":"89","article-title":"Bapineuzumab, an investigational agent for Alzheimer's disease","volume":"38","author":"Khorassani","year":"2013","journal-title":"P T"},{"key":"10.1016\/j.ejphar.2026.178913_bib137","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1177\/2042098617750555","article-title":"An update on the safety of current therapies for Alzheimer's disease: focus on rivastigmine","volume":"9","author":"Khoury","year":"2018","journal-title":"Ther. Adv. Drug Saf."},{"key":"10.1016\/j.ejphar.2026.178913_bib138","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/nrneurol.2011.76","article-title":"The ethics of informed consent in alzheimer disease research","volume":"7","author":"Kim","year":"2011","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.ejphar.2026.178913_bib139","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2019.00103","article-title":"Statins and inflammation: new therapeutic opportunities in psychiatry","volume":"10","author":"Kim","year":"2019","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.ejphar.2026.178913_bib140","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/0092-8674(91)90628-C","article-title":"The trkB tyrosine protein kinase is a receptor for brain-derived neurotrophic factor and neurotrophin-3","volume":"66","author":"Klein","year":"1991","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2026.178913_bib141","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/0896-6273(92)90209-V","article-title":"The trk B tyrosine protein kinase is a receptor for neurotrophin-4","volume":"8","author":"Klein","year":"1992","journal-title":"Neuron"},{"key":"10.1016\/j.ejphar.2026.178913_bib142","doi-asserted-by":"crossref","first-page":"25493","DOI":"10.1074\/jbc.M202651200","article-title":"Intracellular targets of paullones","volume":"277","author":"Knockaert","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2026.178913_bib143","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1056\/NEJM198112173052505","article-title":"Cerebral vasodilators","volume":"305","author":"Koch-Weser","year":"1981","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2026.178913_bib144","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2020.00227","article-title":"Progress of RAGE molecular imaging in alzheimer's disease","volume":"12","author":"Kong","year":"2020","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.ejphar.2026.178913_bib145","doi-asserted-by":"crossref","first-page":"7552","DOI":"10.3390\/ijms26157552","article-title":"The therapeutic potential of glymphatic system activity to reduce the pathogenic accumulation of cytotoxic proteins in alzheimer's disease","volume":"26","author":"Kope\u0107","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2026.178913_bib146","doi-asserted-by":"crossref","first-page":"48","DOI":"10.5056\/jnm18087","article-title":"Brain-gut-microbiota axis in alzheimer's disease","volume":"25","author":"Kowalski","year":"2019","journal-title":"J. Neurogastroenterol. Motil."},{"key":"10.1016\/j.ejphar.2026.178913_bib147","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.3390\/ijms19092714","article-title":"Peptides as therapeutic agents for inflammatory-related diseases","volume":"19","author":"La Manna","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2026.178913_bib148","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13195-018-0340-8","article-title":"Safety, tolerability and immunogenicity of an active anti-A\u03b240 vaccine (ABvac40) in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase I trial","volume":"10","author":"Lacosta","year":"2018","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.ejphar.2026.178913_bib149","doi-asserted-by":"crossref","DOI":"10.4155\/fdd-2022-0005","article-title":"Overcoming the shortcomings of peptide-based therapeutics","volume":"4","author":"Lamers","year":"2022","journal-title":"Future Drug Discov"},{"key":"10.1016\/j.ejphar.2026.178913_bib150","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2015.00403","article-title":"Potential application of lithium in Parkinson's and other neurodegenerative diseases","volume":"9","author":"Lazzara","year":"2015","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.ejphar.2026.178913_bib151","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.neurobiolaging.2010.03.024","article-title":"Human umbilical cord blood-derived mesenchymal stem cells improve neuropathology and cognitive impairment in an Alzheimer's disease mouse model through modulation of neuroinflammation","volume":"33","author":"Lee","year":"2012","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.ejphar.2026.178913_bib152","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1002\/alz.12928","article-title":"Prevalence of dementia in India: national and state estimates from a nationwide study","volume":"19","author":"Lee","year":"2023","journal-title":"Alzheimer's Dementia"},{"key":"10.1016\/j.ejphar.2026.178913_bib153","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0079-6123(09)17506-4","article-title":"Developing novel immunogens for a safe and effective Alzheimer's disease vaccine","volume":"175","author":"Lemere","year":"2009","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.ejphar.2026.178913_bib154","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nrneurol.2009.219","article-title":"Can alzheimer disease be prevented by amyloid-beta immunotherapy?","volume":"6","author":"Lemere","year":"2010","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.ejphar.2026.178913_bib155","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2174\/156720507781788800","article-title":"Novel abeta immunogens: is shorter better?","volume":"4","author":"Lemere","year":"2007","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.ejphar.2026.178913_bib156","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.127414","article-title":"Dual A\u03b2\/tau epitope vaccines: a poorly explored strategy for Alzheimer's disease immunotherapy","volume":"61","author":"Le\u00f3n-Arcia","year":"2025","journal-title":"Vaccine"},{"key":"10.1016\/j.ejphar.2026.178913_bib157","article-title":"Alzheimer's amyloid-\u03b2 A2T variant and its N-terminal peptides inhibit amyloid-\u03b2 fibrillization and rescue the induced cytotoxicity","volume":"12","author":"Lin","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2026.178913_bib158","article-title":"Neuroprotective action of coumarin derivatives through activation of TRKB-CREB-BDNF pathway and reduction of caspase activity in neuronal cells expressing pro-aggregated tau protein","volume":"23","author":"Lin","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2026.178913_bib159","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2017.00969","article-title":"\u03b2-Sheet breaker Peptide-HPYD for the treatment of alzheimer's disease: primary studies on behavioral test and transcriptional profiling","volume":"8","author":"Liu","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.178913_bib160","doi-asserted-by":"crossref","first-page":"787","DOI":"10.4252\/wjsc.v12.i8.787","article-title":"Stem cell therapy for Alzheimer's disease","volume":"12","author":"Liu","year":"2020","journal-title":"World J. Stem Cell."},{"key":"10.1016\/j.ejphar.2026.178913_bib161","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1586\/ern.11.132","article-title":"Use of memantine for the treatment of dementia","volume":"11","author":"Lo","year":"2011","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.ejphar.2026.178913_bib162","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1039\/C3TB21483D","article-title":"Fluorinated beta-sheet breaker peptides","volume":"2","author":"Loureiro","year":"2014","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.ejphar.2026.178913_bib163","doi-asserted-by":"crossref","first-page":"7882","DOI":"10.1021\/bi002734u","article-title":"Structure\u2212Function relationships for inhibitors of \u03b2-Amyloid toxicity containing the recognition sequence KLVFF","volume":"40","author":"Lowe","year":"2001","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejphar.2026.178913_bib164","series-title":"ALZFORUM","year":"2016"},{"key":"10.1016\/j.ejphar.2026.178913_bib165","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1212\/01.wnl.0000260269.93245.d2","article-title":"Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial","volume":"68","author":"Lyketsos","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2026.178913_bib166","article-title":"A surgical therapy for Alzheimer's disease with lymphaticovenular anastomosis","volume":"9","author":"Ma","year":"2025","journal-title":"J. Alzheimers Dis. Rep."},{"key":"10.1016\/j.ejphar.2026.178913_bib167","doi-asserted-by":"crossref","first-page":"15262","DOI":"10.1021\/acs.jmedchem.1c01300","article-title":"Discovery of umibecestat (CNP520): a potent, selective, and efficacious \u03b2-Secretase (BACE1) inhibitor for the prevention of alzheimer's disease","volume":"64","author":"Machauer","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2026.178913_bib168","doi-asserted-by":"crossref","first-page":"6921","DOI":"10.3390\/ijms24086921","article-title":"Cholinergic antagonists and behavioral disturbances in neurodegenerative diseases","volume":"24","author":"Mahmoudi","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2026.178913_bib169","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3390\/ph12010041","article-title":"BACE-1 and \u03b3-Secretase as therapeutic targets for alzheimer's disease","volume":"12","author":"Maia","year":"2019","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejphar.2026.178913_bib170","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1002\/cbic.202100287","article-title":"Potent tau aggregation inhibitor d\u2010peptides selected against tau\u2010repeat 2 using mirror image phage display","volume":"22","author":"Malhis","year":"2021","journal-title":"Chembiochem"},{"key":"10.1016\/j.ejphar.2026.178913_bib171","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/7303096","article-title":"Metformin and its sulfenamide prodrugs inhibit human cholinesterase activity","volume":"2017","author":"Markowicz-Piasecka","year":"2017","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.ejphar.2026.178913_bib172","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.3390\/molecules25174005","article-title":"Memantine derivatives as multitarget agents in alzheimer's disease","volume":"25","author":"Marotta","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.ejphar.2026.178913_bib173","doi-asserted-by":"crossref","first-page":"7348","DOI":"10.1021\/jm801252w","article-title":"Discovery of begacestat, a Notch-1-Sparing \u03b3-Secretase inhibitor for the treatment of alzheimer's disease","volume":"51","author":"Mayer","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2026.178913_bib174","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0304-4165(03)00117-X","article-title":"Subcellular localization of human glyceraldehyde-3-phosphate dehydrogenase is independent of its glycolytic function","volume":"1622","author":"Mazzola","year":"2003","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"10.1016\/j.ejphar.2026.178913_bib175","doi-asserted-by":"crossref","first-page":"609","DOI":"10.9758\/cpn.23.1081","article-title":"Dextromethorphan-bupropion (auvelity) for the treatment of major depressive disorder","volume":"21","author":"McCarthy","year":"2023","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"10.1016\/j.ejphar.2026.178913_bib176","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000006277","article-title":"Longitudinal cognitive and biomarker changes in dominantly inherited alzheimer disease","volume":"91","author":"McDade","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2026.178913_bib177","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1046\/j.1365-2125.1999.00026.x","article-title":"Acetylcholinesterase inhibitors in Alzheimer's disease","volume":"48","author":"McGleenon","year":"1999","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.178913_bib178","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222313168","article-title":"A review of the current mammalian models of alzheimer's disease and challenges that need to be overcome","volume":"22","author":"Mckean","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2026.178913_bib179","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1042\/BJ20110512","article-title":"Reduction in BACE1 decreases body weight, protects against diet-induced obesity and enhances insulin sensitivity in mice","volume":"441","author":"Meakin","year":"2012","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejphar.2026.178913_bib180","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1080\/13543784.2017.1323868","article-title":"Why do trials for Alzheimer's disease drugs keep failing? A discontinued drug perspective for 2010-2015","volume":"26","author":"Mehta","year":"2017","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.ejphar.2026.178913_bib181","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1039\/D0MD00196A","article-title":"Recent developments of small molecule \u03b3-secretase modulators for Alzheimer's disease","volume":"11","author":"Mekala","year":"2020","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejphar.2026.178913_bib182","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1039\/D0MD00196A","article-title":"Recent developments of small molecule \u03b3-secretase modulators for Alzheimer's disease","volume":"11","author":"Mekala","year":"2020","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejphar.2026.178913_bib183","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2014.00165","article-title":"\u03b2-secretase inhibitor: a promising novel therapeutic drug in Alzheimer's disease","volume":"6","author":"Menting","year":"2014","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.ejphar.2026.178913_bib184","series-title":"Araclon Biotech Presents Positive Final Results from Phase 2 Clinical Study of ABvac40 Alzheimer's Vaccine at CTAD","year":"2023"},{"key":"10.1016\/j.ejphar.2026.178913_bib185","series-title":"ALZFORUM","year":"2024"},{"key":"10.1016\/j.ejphar.2026.178913_bib186","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/nrn2738","article-title":"TrkB signalling pathways in LTP and learning","volume":"10","author":"Minichiello","year":"2009","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.ejphar.2026.178913_bib187","doi-asserted-by":"crossref","first-page":"11242","DOI":"10.1074\/jbc.M113.537472","article-title":"Computational and experimental studies on \u03b2-Sheet breakers targeting A\u03b21\u201340 fibrils","volume":"289","author":"Minicozzi","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2026.178913_bib188","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.2174\/1871527313666140917112248","article-title":"Protein interactions between the C-Terminus of A\u03b2-Peptide and phospholipase A2 - a structure biology based approach to identify novel alzheimer's therapeutics","volume":"13","author":"Mirza","year":"2014","journal-title":"CNS Neurol. Disord.: Drug Targets"},{"key":"10.1016\/j.ejphar.2026.178913_bib189","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2017.00030","article-title":"Therapeutic potential of secreted amyloid precursor protein APPs\u03b1","volume":"10","author":"Mockett","year":"2017","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.ejphar.2026.178913_bib190","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/jcsm.12654","article-title":"Effects of statins on mitochondrial pathways","volume":"12","author":"Mollazadeh","year":"2021","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.ejphar.2026.178913_bib191","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1365-2613.2007.00568.x","article-title":"Cleavage and conformational changes of tau protein follow phosphorylation during Alzheimer's disease","volume":"89","author":"Mondrag\u00f3n\u2010Rodr\u00edguez","year":"2008","journal-title":"Int. J. Exp. Pathol."},{"key":"10.1016\/j.ejphar.2026.178913_bib192","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3233\/JAD-131535","article-title":"Glutaminyl cyclase in human cortex: correlation with (pGlu)-Amyloid-\u03b2 load and cognitive decline in alzheimer's disease","volume":"39","author":"Morawski","year":"2014","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.ejphar.2026.178913_bib193","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1586\/17512433.2013.827403","article-title":"Davunetide: a review of safety and efficacy data with a focus on neurodegenerative diseases","volume":"6","author":"Morimoto","year":"2013","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.178913_bib194","doi-asserted-by":"crossref","DOI":"10.4155\/fso.15.73","article-title":"The case of galantamine: repurposing and late blooming of a cholinergic drug","volume":"1","author":"Mucke","year":"2015","journal-title":"Future Sci. OA"},{"key":"10.1016\/j.ejphar.2026.178913_bib195","article-title":"FDA approves third anti-amyloid antibody for alzheimer disease","volume":"23","author":"Mullard","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejphar.2026.178913_bib196","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/nm.1912","article-title":"Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease","volume":"15","author":"Nagahara","year":"2009","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2026.178913_bib197","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/toxsci\/kft224","article-title":"E2012-Induced cataract and its predictive biomarkers","volume":"137","author":"Nakano-Ito","year":"2014","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.ejphar.2026.178913_bib198","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3390\/pharmaceutics16010060","article-title":"Monoclonal antibody therapy in alzheimer's disease","volume":"16","author":"Nea\u021bu","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejphar.2026.178913_bib199","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00401-014-1347-2","article-title":"The multifaceted nature of amyloid precursor protein and its proteolytic fragments: friends and foes","volume":"129","author":"Nhan","year":"2015","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.ejphar.2026.178913_bib200","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1080\/07853890.2021.1966088","article-title":"Role of neurotoxicants in the pathogenesis of Alzheimer's disease: a mechanistic insight","volume":"53","author":"Nisa","year":"2021","journal-title":"Ann. Med."},{"key":"10.1016\/j.ejphar.2026.178913_bib201","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1021\/acschembio.3c00219","article-title":"Tacrine first-phase biotransformation and associated hepatotoxicity: a possible way to avoid quinone methide formation","volume":"18","author":"Novak","year":"2023","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejphar.2026.178913_bib202","first-page":"1359","article-title":"Profile of gantenerumab and its potential in the treatment of Alzheimer's disease","volume":"7","author":"Novakovic","year":"2013","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.ejphar.2026.178913_bib203","author":"Orr"},{"key":"10.1016\/j.ejphar.2026.178913_bib204","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1001\/jamaneurol.2022.2909","article-title":"Evaluating the safety and efficacy of crenezumab vs placebo in adults with early alzheimer disease","volume":"79","author":"Ostrowitzki","year":"2022","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ejphar.2026.178913_bib205","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2014.00062","article-title":"Current challenges in peptide-based drug discovery","volume":"2","author":"Otvos","year":"2014","journal-title":"Front. Chem."},{"key":"10.1016\/j.ejphar.2026.178913_bib206","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jalz.2009.06.003","article-title":"Alzheimer's disease drug development and the problem of the blood-brain barrier","volume":"5","author":"Pardridge","year":"2009","journal-title":"Alzheimer's Dement."},{"key":"10.1016\/j.ejphar.2026.178913_bib207","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1212\/01.wnl.0000435291.49598.54","article-title":"Neurovascular decoupling is associated with severity of cerebral amyloid angiopathy","volume":"81","author":"Peca","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2026.178913_bib208","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1007\/s00044-024-03269-1","article-title":"Peptide-based therapeutics: challenges and solutions","volume":"33","author":"Pereira","year":"2024","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.ejphar.2026.178913_bib209","article-title":"Cerebral hemorrhage after passive Anti-A\u03b2 immunotherapy","volume":"298","author":"Pfeifer","year":"2002","journal-title":"Science (1979)"},{"key":"10.1016\/j.ejphar.2026.178913_bib210","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/(SICI)1097-4695(19990605)39:3<371::AID-NEU4>3.0.CO;2-E","article-title":"Beta-sheet breaker peptide inhibitor of Alzheimer's amyloidogenesis with increased blood-brain barrier permeability and resistance to proteolytic degradation in plasma","volume":"39","author":"Poduslo","year":"1999","journal-title":"J. Neurobiol."},{"key":"10.1016\/j.ejphar.2026.178913_bib211","series-title":"Clinical Trials on Alzheimer's Disease (CTAD) Conference 2023","article-title":"RG6289, a new \u03b3-secretase modulator for the treatment of Alzheimer's disease: dose selection for a phase II trial based on population PK\/PD modeling","author":"Portron","year":"2023"},{"key":"10.1016\/j.ejphar.2026.178913_bib212","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1159\/000113700","article-title":"Progress in the active immunotherapeutic approach to alzheimer's disease: clinical investigations into AN1792-Associated meningoencephalitis","volume":"5","author":"Pride","year":"2008","journal-title":"Neurodegener. Dis."},{"key":"10.1016\/j.ejphar.2026.178913_bib213","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s44194-024-00035-8","article-title":"Alzheimer's disease and immunotherapy","volume":"3","author":"Qin","year":"2024","journal-title":"Curr. Med."},{"key":"10.1016\/j.ejphar.2026.178913_bib214","doi-asserted-by":"crossref","first-page":"111","DOI":"10.31887\/DCNS.2009.11.2\/cqiu","article-title":"Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention","volume":"11","author":"Qiu","year":"2009","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.ejphar.2026.178913_bib215","doi-asserted-by":"crossref","first-page":"581","DOI":"10.3233\/JAD-190228","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamic effects of PF-06751979, a potent and selective oral BACE1 inhibitor: results from phase I studies in healthy adults and healthy older subjects","volume":"71","author":"Qiu","year":"2019","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.ejphar.2026.178913_bib216","doi-asserted-by":"crossref","first-page":"532","DOI":"10.3390\/ph18040532","article-title":"An overview of the effects of lithium on alzheimer's disease: a historical perspective","volume":"18","author":"Radanovic","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejphar.2026.178913_bib217","doi-asserted-by":"crossref","first-page":"8139","DOI":"10.1038\/srep08139","article-title":"Rationally designed peptidomimetic modulators of A\u03b2 toxicity in alzheimer's disease","volume":"5","author":"Rajasekhar","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2026.178913_bib218","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/978-1-4939-9068-9_7","article-title":"Cisterna magna injection in rats to study glymphatic function","author":"Ramos","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ejphar.2026.178913_bib219","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232112841","article-title":"Phosphorylated tau in alzheimer's disease and other tauopathies","volume":"23","author":"Rawat","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2026.178913_bib220","doi-asserted-by":"crossref","first-page":"868","DOI":"10.3390\/brainsci10110868","article-title":"The sleeping brain: harnessing the power of the glymphatic system through lifestyle choices","volume":"10","author":"Reddy","year":"2020","journal-title":"Brain Sci."},{"key":"10.1016\/j.ejphar.2026.178913_bib221","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci10110868","article-title":"The sleeping brain: harnessing the power of the glymphatic system through lifestyle choices","volume":"10","author":"Reddy","year":"2020","journal-title":"Brain Sci."},{"key":"10.1016\/j.ejphar.2026.178913_bib222","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1750-1326-7-61","article-title":"Modulation of \u03b3-secretase by EVP-0015962 reduces amyloid deposition and behavioral deficits in Tg2576 mice","volume":"7","author":"Rogers","year":"2012","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.ejphar.2026.178913_bib223","doi-asserted-by":"crossref","first-page":"742","DOI":"10.2174\/13892037113149990144","article-title":"CHF5074 reduces biomarkers of neuroinflammation in patients with mild cognitive impairment: a 12-Week, double-blind, Placebo- controlled study","volume":"10","author":"Ross","year":"2013","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.ejphar.2026.178913_bib224","doi-asserted-by":"crossref","DOI":"10.1016\/j.crstbi.2024.100124","article-title":"Identification of coumarin derivatives targeting acetylcholinesterase for Alzheimer's disease by field-based 3D-QSAR, pharmacophore model-based virtual screening, molecular docking, MM\/GBSA, ADME and MD simulation study","volume":"7","author":"Saha","year":"2024","journal-title":"Curr. Res. Struct. Biol."},{"key":"10.1016\/j.ejphar.2026.178913_bib225","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108104","article-title":"Tau immunotherapies: lessons learned, current status and future considerations","volume":"175","author":"Sandusky-Beltran","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2026.178913_bib226","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/s41398-022-02254-9","article-title":"Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study","volume":"12","author":"Sauder","year":"2022","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.ejphar.2026.178913_bib227","doi-asserted-by":"crossref","first-page":"3645","DOI":"10.1021\/acsptsci.4c00400","article-title":"Neprilysin-mediated amyloid beta clearance and its therapeutic implications in neurodegenerative disorders","volume":"7","author":"Saxena","year":"2024","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.ejphar.2026.178913_bib228","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13195-018-0431-6","article-title":"Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a study","volume":"10","author":"Scheltens","year":"2018","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.ejphar.2026.178913_bib229","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s13195-021-00934-0","article-title":"The association of antidiabetic medications and mini-mental state examination scores in patients with diabetes and dementia","volume":"13","author":"Secnik","year":"2021","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.ejphar.2026.178913_bib230","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/nchem.2889","article-title":"Structure-based inhibitors of tau aggregation","volume":"10","author":"Seidler","year":"2018","journal-title":"Nat. Chem."},{"key":"10.1016\/j.ejphar.2026.178913_bib231","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1038\/s43587-023-00523-w","article-title":"TANGO: a placebo-controlled randomized phase 2 study of efficacy and safety of the anti-tau monoclonal antibody gosuranemab in early Alzheimer's disease","volume":"3","author":"Shulman","year":"2023","journal-title":"Nat. Aging"},{"key":"10.1016\/j.ejphar.2026.178913_bib232","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature10154","article-title":"Structure-based design of non-natural amino-acid inhibitors of amyloid fibril formation","volume":"475","author":"Sievers","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2026.178913_bib233","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s42466-021-00102-7","article-title":"Glymphatic system, AQP4, and their implications in Alzheimer's disease","volume":"3","author":"Silva","year":"2021","journal-title":"Neurol. Res. Pract"},{"key":"10.1016\/j.ejphar.2026.178913_bib234","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3390\/biom6010006","article-title":"Tau protein hyperphosphorylation and aggregation in alzheimer's disease and other tauopathies, and possible neuroprotective strategies","volume":"6","author":"\u0160imi\u0107","year":"2016","journal-title":"Biomolecules"},{"key":"10.1016\/j.ejphar.2026.178913_bib235","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic alzheimer disease","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.ejphar.2026.178913_bib236","doi-asserted-by":"crossref","DOI":"10.1016\/j.jff.2023.105915","article-title":"Gut-brain axis and Alzheimer's disease: therapeutic interventions and strategies","volume":"112","author":"Singh","year":"2024","journal-title":"J. Funct.Foods"},{"key":"10.1016\/j.ejphar.2026.178913_bib237","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1097\/JGP.0b013e31818cd3a4","article-title":"Cognitive and cerebral metabolic effects of celecoxib versus placebo in people with age-related memory loss: randomized controlled study","volume":"16","author":"Small","year":"2008","journal-title":"Am. J. Geriatr. Psychiatr."},{"key":"10.1016\/j.ejphar.2026.178913_bib238","unstructured":"Solanezumab [WWW Document], n.d. . ALZFORUM. URL https:\/\/www.alzforum.org\/therapeutics\/solanezumab (accessed 8.28.25)."},{"key":"10.1016\/j.ejphar.2026.178913_bib239","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1001\/jamaneurol.2020.4857","article-title":"Findings of efficacy, safety, and biomarker outcomes of atabecestat in preclinical alzheimer disease","volume":"78","author":"Sperling","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ejphar.2026.178913_bib240","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJMoa2305032","article-title":"Trial of solanezumab in preclinical alzheimer's disease","volume":"389","author":"Sperling","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2026.178913_bib241","series-title":"Rapamycin - Effects on Alzheimer's and Cognitive Health - NCT04629495","author":"Sudha","year":"2024"},{"key":"10.1016\/j.ejphar.2026.178913_bib242","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3233\/JAD-2006-9S350","article-title":"Tacrine, and Alzheimer's treatments","volume":"9","author":"Summers","year":"2006","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.ejphar.2026.178913_bib243","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1212\/01.wnl.0000284596.95156.48","article-title":"NSAID use and dementia risk in the cardiovascular health study","volume":"70","author":"Szekely","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2026.178913_bib244","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1172\/JCI124853","article-title":"APOE4-mediated amyloid-\u03b2 pathology depends on its neuronal receptor LRP1","volume":"129","author":"Tachibana","year":"2019","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejphar.2026.178913_bib245","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006296","article-title":"The genetics of alzheimer disease","volume":"2","author":"Tanzi","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.ejphar.2026.178913_bib246","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1001\/jamaneurol.2022.1375","article-title":"Safety and efficacy of semorinemab in individuals with prodromal to mild alzheimer disease","volume":"79","author":"Teng","year":"2022","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ejphar.2026.178913_bib247","doi-asserted-by":"crossref","first-page":"8545","DOI":"10.1074\/jbc.271.15.8545","article-title":"Arrest of -Amyloid fibril formation by a pentapeptide ligand","volume":"271","author":"Tjernberg","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2026.178913_bib248","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.cellsig.2010.08.003","article-title":"The diverse functions of GAPDH: views from different subcellular compartments","volume":"23","author":"Tristan","year":"2011","journal-title":"Cell. Signal."},{"key":"10.1016\/j.ejphar.2026.178913_bib249","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1001\/jamaneurol.2019.3812","article-title":"Reactions to multiple ascending doses of the microtubule stabilizer TPI-287 in patients with alzheimer disease, progressive supranuclear palsy, and corticobasal syndrome","volume":"77","author":"Tsai","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ejphar.2026.178913_bib250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2020\/7039138","article-title":"Novel anti-alzheimer\u2019s therapeutic molecules targeting amyloid precursor protein processing","author":"Uddin","year":"2020","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.ejphar.2026.178913_bib251","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14283\/jpad.2016.91","article-title":"VANUTIDE CRIDIFICAR (ACC-001) and QS-21 adjuvant in individuals with early ALZHEIMER\u2019S disease: amyloid imaging positron emission tomography and safety results from a phase 2 study","author":"van Dyck","year":"2016","journal-title":"J. Prev. Alzheimers Dis."},{"key":"10.1016\/j.ejphar.2026.178913_bib252","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early alzheimer's disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2026.178913_bib253","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13195-024-01382-2","article-title":"A pilot study to evaluate the effect of CT1812 treatment on synaptic density and other biomarkers in Alzheimer's disease","volume":"16","author":"van Dyck","year":"2024","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.ejphar.2026.178913_bib254","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jpba.2015.03.023","article-title":"Toward greener analytical techniques for the absolute quantification of peptides in pharmaceutical and biological samples","volume":"113","author":"Van Eeckhaut","year":"2015","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejphar.2026.178913_bib255","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1002\/cmdc.200800273","article-title":"Reduction of alzheimer's disease amyloid plaque load in transgenic mice by D3, a <scp>D<\/scp> \u2010enantiomeric peptide identified by mirror image phage display","volume":"3","author":"van Groen","year":"2008","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejphar.2026.178913_bib256","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.3390\/jcm12051709","article-title":"Advances in neurodegenerative diseases","volume":"12","author":"Van Schependom","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ejphar.2026.178913_bib257","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.3390\/vaccines9111278","article-title":"Peptide-based vaccines for neurodegenerative diseases: recent endeavors and future perspectives","volume":"9","author":"Vassilakopoulou","year":"2021","journal-title":"Vaccines (Basel)."},{"key":"10.1016\/j.ejphar.2026.178913_bib258","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173554","article-title":"Alzheimer's disease: recent treatment strategies","volume":"887","author":"Vaz","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.178913_bib259","doi-asserted-by":"crossref","DOI":"10.1051\/epjconf\/202634801002","article-title":"Challenges in alzheimer's drug development: failures, therapeutic barriers and clinical translation","volume":"348","author":"Vediya","year":"2026","journal-title":"EPJ Web Conf."},{"key":"10.1016\/j.ejphar.2026.178913_bib260","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1212\/01.wnl.0000311269.57716.63","article-title":"Protective effects of NSAIDs on the development of alzheimer disease","volume":"70","author":"Vlad","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2026.178913_bib261","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24043895","article-title":"Alzheimer's disease: a brief history of immunotherapies targeting amyloid \u03b2","volume":"24","author":"Vogt","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2026.178913_bib262","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1001\/jamaneurol.2021.3310","article-title":"Effect of levetiracetam on cognition in patients with alzheimer disease with and without epileptiform activity","volume":"78","author":"Vossel","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ejphar.2026.178913_bib263","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.neurol.2025.07.016","article-title":"The challenging concept of preclinical Alzheimer's disease","volume":"181","author":"Wallon","year":"2025","journal-title":"Rev. Neurol. (Paris)."},{"key":"10.1016\/j.ejphar.2026.178913_bib264","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3233\/JAD-160763","article-title":"Role of glutamate and NMDA receptors in alzheimer's disease","volume":"57","author":"Wang","year":"2017","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.ejphar.2026.178913_bib265","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41392-022-00904-4","article-title":"Therapeutic peptides: current applications and future directions","volume":"7","author":"Wang","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejphar.2026.178913_bib266","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci14111064","article-title":"Photobiomodulation as a potential treatment for alzheimer's disease: a review paper","volume":"14","author":"Wang","year":"2024","journal-title":"Brain Sci."},{"key":"10.1016\/j.ejphar.2026.178913_bib267","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1001\/jama.1994.03510370044030","article-title":"Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease","volume":"271","author":"Watkins","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.ejphar.2026.178913_bib268","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0235-19.2019","article-title":"Transcranial magnetic stimulation in alzheimer's disease: are we ready?","volume":"7","author":"Weiler","year":"2020","journal-title":"eNeuro"},{"key":"10.1016\/j.ejphar.2026.178913_bib269","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1073\/pnas.72.5.1858","article-title":"A protein factor essential for microtubule assembly","volume":"72","author":"Weingarten","year":"1975","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejphar.2026.178913_bib270","doi-asserted-by":"crossref","first-page":"7673","DOI":"10.1039\/C7CC03102E","article-title":"Stabilizing amyloid-\u03b2 peptide by the N-terminus capture is capable of preventing and eliminating amyloid-\u03b2 oligomers","volume":"53","author":"Wen","year":"2017","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejphar.2026.178913_bib271","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/jamaneurol.2019.3988","article-title":"Efficacy and safety of lanabecestat for treatment of early and mild alzheimer disease","volume":"77","author":"Wessels","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ejphar.2026.178913_bib272","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.3233\/ADR-230012","article-title":"Safety, tolerability, and pharmacokinetics of zagotenemab in participants with symptomatic alzheimer's disease: a phase I clinical trial","volume":"7","author":"Willis","year":"2023","journal-title":"J. Alzheimers Dis. Rep."},{"key":"10.1016\/j.ejphar.2026.178913_bib273","doi-asserted-by":"crossref","first-page":"160","DOI":"10.2174\/187152709787847289","article-title":"AD vaccines: conclusions and future directions","volume":"8","author":"Wisniewski","year":"2009","journal-title":"CNS Neurol. Disord.: Drug Targets"},{"key":"10.1016\/j.ejphar.2026.178913_bib274","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.nurt.2008.05.010","article-title":"Inhibition and modulation of \u03b3-Secretase for alzheimer's disease","volume":"5","author":"Wolfe","year":"2008","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.ejphar.2026.178913_bib275","series-title":"Eisai and Biogen to Discontinue Phase III Clinical Studies of BACE Inhibitor Elenbecestat in Early Alzheimer's Disease- Discontinuation of Studies Based on Data Safety Monitoring Board Recommendation","author":"Woodcliff Lake","year":"2019"},{"key":"10.1016\/j.ejphar.2026.178913_bib276","series-title":"WHO Issues New and Updated Recommendations on Treatment of Mental, Neurological and Substance Use Conditions","year":"2023"},{"key":"10.1016\/j.ejphar.2026.178913_bib277","first-page":"303","author":"Xu","year":"2012","journal-title":"Striatal-Enriched Protein Tyrosine Phosphatase in Alzheimer\u2019s Disease"},{"key":"10.1016\/j.ejphar.2026.178913_bib278","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccr.2022.214726","article-title":"Photodynamic Alzheimer's disease therapy: from molecular catalysis to photo-nanomedicine","volume":"470","author":"Xu","year":"2022","journal-title":"Coord. Chem. Rev."},{"key":"10.1016\/j.ejphar.2026.178913_bib279","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1007\/s13311-023-01405-0","article-title":"Anti-amyloid immunotherapies for alzheimer's disease: a 2023 clinical update","volume":"20","author":"Yadollahikhales","year":"2023","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.ejphar.2026.178913_bib280","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s43856-024-00527-6","article-title":"Combined use of donepezil and memantine increases the probability of five-year survival of Alzheimer's disease patients","volume":"4","author":"Yaghmaei","year":"2024","journal-title":"Commun. Med."},{"key":"10.1016\/j.ejphar.2026.178913_bib281","first-page":"1","author":"Yang","year":"2015","journal-title":"Peptide Immunotherapy in Vaccine Development"},{"key":"10.1016\/j.ejphar.2026.178913_bib282","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2022.1019412","article-title":"Small-molecule drugs development for Alzheimer's disease","volume":"14","author":"Yao","year":"2022","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.ejphar.2026.178913_bib283","doi-asserted-by":"crossref","DOI":"10.1177\/1179573520907397","article-title":"Current and future treatments in alzheimer disease: an update","volume":"12","author":"Yiannopoulou","year":"2020","journal-title":"J. Cent. Nerv. Syst. Dis."},{"key":"10.1016\/j.ejphar.2026.178913_bib284","doi-asserted-by":"crossref","DOI":"10.12659\/MSM.933084","article-title":"The role of amyloid-beta and tau in the early pathogenesis of alzheimer's disease","volume":"27","author":"Yin","year":"2021","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.ejphar.2026.178913_bib285","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1038\/s41467-025-58726-1","article-title":"Long-term physical exercise facilitates putative glymphatic and meningeal lymphatic vessel flow in humans","volume":"16","author":"Yoo","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejphar.2026.178913_bib286","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104665","article-title":"Safety, tolerability, immunogenicity, and efficacy of UB-311 in participants with mild Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 2a study","volume":"94","author":"Yu","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ejphar.2026.178913_bib287","doi-asserted-by":"crossref","first-page":"10561","DOI":"10.1523\/JNEUROSCI.2666-08.2008","article-title":"The tyrosine phosphatase STEP mediates AMPA receptor endocytosis after metabotropic glutamate receptor stimulation","volume":"28","author":"Zhang","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejphar.2026.178913_bib288","doi-asserted-by":"crossref","first-page":"4240","DOI":"10.1021\/acschemneuro.0c00518","article-title":"Selection of a <scp>d<\/scp> -Enantiomeric peptide specifically binding to PHF6 for inhibiting tau aggregation in transgenic mice","volume":"11","author":"Zhang","year":"2020","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejphar.2026.178913_bib289","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/s41392-023-01484-7","article-title":"Amyloid \u03b2-based therapy for Alzheimer's disease: challenges, successes and future","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejphar.2026.178913_bib290","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/s41380-024-02691-6","article-title":"Melatonin: a potential nighttime guardian against Alzheimer's","volume":"30","author":"Zhang","year":"2025","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.ejphar.2026.178913_bib291","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.721135","article-title":"GLP-1 receptor agonists: beyond their pancreatic effects","volume":"12","author":"Zhao","year":"2021","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.ejphar.2026.178913_bib292","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41392-023-01557-7","article-title":"Vaccine adjuvants: mechanisms and platforms","volume":"8","author":"Zhao","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejphar.2026.178913_bib293","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40035-025-00510-8","article-title":"Targeting the glymphatic system: a\u03b2 accumulation and phototherapy strategies across different stages of Alzheimer's disease","volume":"14","author":"Zhao","year":"2025","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.ejphar.2026.178913_bib294","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1021\/acs.jpcb.5b08177","article-title":"Mechanism of C-Terminal fragments of amyloid \u03b2-Protein as A\u03b2 inhibitors: do C-Terminal interactions play a key role in their inhibitory activity?","volume":"120","author":"Zheng","year":"2016","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.ejphar.2026.178913_bib295","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejphar.2026.178913_bib296","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/toxsci\/kfad057","article-title":"Mechanistic investigation of liver injury induced by BMS-932481, an experimental \u0263-secretase modulator","volume":"194","author":"Zhuo","year":"2023","journal-title":"Toxicol. Sci."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001429992600395X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001429992600395X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T06:55:05Z","timestamp":1779000905000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001429992600395X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":295,"alternative-id":["S001429992600395X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.178913","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From pathology to precision therapy: Contemporary and emerging strategies in Alzheimer's disease treatment","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.178913","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"178913"}}